Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its New Drug Application (NDA) for the Category 1 product GST-HG171/ritonavir, an oral therapy for COVID-19, has been accepted for review by China’s National Medical Products Administration (NMPA).
Therapeutic Profile of GST-HG171/Ritonavir
GST-HG171 is identified as a 3CL protease (3CLpro) inhibitor, which is recognized for its broad-spectrum anti-COVID-19 activity. This inhibitor targets the 3CLpro enzyme, which plays a crucial role in the replication of the SARS-CoV-2 virus. Ritonavir, developed by AbbVie, is an oral anti-viral pharmacokinetic enhancer that boosts the effectiveness of other anti-viral drugs by inhibiting their metabolism, thereby increasing their concentration in the body.
Significance of the NDA Acceptance
The acceptance of the NDA for GST-HG171/ritonavir by the NMPA marks a significant step forward in the potential approval and commercialization of this oral COVID-19 therapy in China. This development highlights Fujian Cosunter Pharmaceutical’s commitment to contributing to the global fight against the pandemic through the development of effective and accessible treatments.- Flcube.com
